Psyence Group Completes Export of Psilocybin Mushrooms to Canada
TORONTO, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”) has...
Neurology
Frontera Therapeutics Receives Additional IND Clearance for its Lead Program FT-001
China CDE accepts Investigational New Drug (IND) application for lead gene therapy product candidate, FT-001, for the treatment of a...
electroCore Strengthens Patent Portfolio with Issuance of Four New U.S. Patents
Four patents issued expanding claims related to delivery of nVNS and other therapies using mobile devicesROCKAWAY, N.J., Sept. 21, 2022...
Mapi Pharma Announces Positive Top-Line Results from GA Depot Phase III Trial for Relapsing forms of Multiple Sclerosis (RMS)
The study evaluating a long-acting glatiramer acetate injection, GA Depot 40 mg once every four weeks, met the primary endpoint,...
Satsuma Pharmaceuticals Announces Positive Results from the Ongoing STS101 ASCEND Phase 3 Open-label, Long-term Safety Trial
STS101 demonstrated a favorable safety and tolerability profile, consistent with clinical experience to dateOver 8,000 migraine attacks treated with more...
Electrocore Announces Date for Fiscal Year 2022 Annual Meeting and Deadlines for Stockholder Proposals
ROCKAWAY, N.J., Sept. 20, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) (the “Company”), a commercial-stage bioelectronic medicine company, today...
GNT Pharma Provides Update on Two Phase III Studies of Nelonemdaz for Acute Ischemic Stroke Patients Treated with tPA (ENIS-3) or Endovascular Thrombectomy (RODIN)
Promising efficacy and safety profiles were observed in prior Phase II studies in acute ischemic stroke patients treated with recanalization...
Ashvattha Therapeutics Announces Presentations of Preclinical Data on Hydroxyl Dendrimer-Based PET Tracer [18F]OP-801 at the 2022 World Molecular Imaging Congress (WMIC)
– Scientific collaborators at Stanford University will present data on an imaging and treatment regimen demonstrating the microglial targeting of...
Pasithea Therapeutics Further Strengthens its Scientific Advisory Board with the Appointment of Dr. Merit Cudkowicz
-- Dr. Cudkowicz is a pioneer in the study and treatment of people with Amyotrophic Lateral Sclerosis (ALS) and other...
Pharma Two B Presents Positive Efficacy and Safety Data of P2B001 from Phase 3 Trial at the MDS International Congress of Parkinson’s Disease and Movement Disorders®
P2B001 is a novel proprietary fixed-dose combination of extended-release (ER) formulations of low doses of pramipexole and rasagiline; both doses...
BioJiva Reports Results of Pilot Phase 2 Clinical Trial of RT001 in Patients with Amyotrophic Lateral Sclerosis (ALS)
Signals of Clinical Benefit Detected in Small Phase 2 Study, Suggesting Potential to Show Statistically Significant Therapeutic Benefit in Larger,...
Assertio to Participate in the 2022 Lake Street BIG6 Conference
LAKE FOREST, Ill., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (Nasdaq: ASRT), a specialty...
TG Therapeutics Announces Results from the ULTIMATE I & II Phase 3 Trials of Investigational Ublituximab in RMS Published in The New England Journal of Medicine
Ublituximab is an investigational targeted B-cell therapy that shows superior efficacy when compared with teriflunomide, a commonly prescribed oral treatment...
BetterLife Lead Drug (BETR-001) Promotes Structural Neural Plasticity with Possible Nootropic Effects Similar to That of LSD Without Hallucinogenic Side Effects
VANCOUVER, British Columbia, Aug. 24, 2022 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF...
Plus Therapeutics to Present Data from ReSPECT-GBM™ Clinical Trial at the European Society for Medical Oncology Congress 2022
AUSTIN, Texas, Aug. 23, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative,...
Assertio Prices $60 Million Convertible Senior Notes Offering to Refinance Existing 13% Senior Secured Notes Due 2024
LAKE FOREST, Ill., Aug. 22, 2022 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty...
Long COVID-19 study identifies novel blood markers as potential diagnostic and therapeutic targets
World first study utilizing Somalogic SomaScan® assay# to assess up to 7,000 plasma proteins in Long COVID-19 patients has elucidated...
Assure Holdings Corp. Prices $6.2 Million Underwritten Public Offering of Common Stock
DENVER, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (NASDAQ: IONM) ("Assure Holdings" or the "Company"), a provider of...
Assure Holdings Corp. Announces Proposed Underwritten Public Offering of Common Stock
DENVER, Aug. 19, 2022 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (NASDAQ: IONM) ("Assure Holdings" or the "Company"), a provider of...
Plus Therapeutics Presents Positive Data from Ongoing ReSPECT™ Clinical Trials at the Annual Conference on CNS Clinical Trials and Brain Metastases
AUSTIN, Texas, Aug. 13, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative,...
